Little Green Pharma (ASX:LGP) Research & Development: A$0.05 Mil (TTM As of Mar. 2026)


What is Little Green Pharma Research & Development?

Little Green Pharma ASX:LGP Research & Development is A$0.05 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Little Green Pharma's Research & Development for the six months ended in Mar. 2026 was A$0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.05 Mil.

Little Green Pharma  (ASX:LGP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Little Green Pharma Research & Development Related Terms

Little Green Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Little Green Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma Research & Development Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 1.78 6.60 6.32 0.29 0.05

Little Green Pharma Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 0.25 0.04 0.04 0.01

Little Green Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.05 Mil mean?
Little Green Pharma (ASX:LGP) has a Research & Development of A$0.05 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Little Green Pharma and its competitors.
Is Little Green Pharma's Research & Development too high?
Little Green Pharma's current Research & Development is A$0.05 Mil.
How does Little Green Pharma's Research & Development compare to ZTS?
Little Green Pharma's Research & Development of A$0.05 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Little Green Pharma and its competitors. Little Green Pharma's current Research & Development is A$0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current Research & Development is A$0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current Research & Development is A$0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Little Green Pharma Business Description

Address 13A Bedbrook Place, Shenton Park, West Perth, Perth, WA, AUS, 6008
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).